Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Terminal complement inhibition is the standard of care for atypical hemolytic uremic syndrome (aHUS). The optimal duration of complement inhibition is unknown, although indefinite therapy is common. Here, we present the outcomes of a physician-directed eculizumab discontinuation and monitoring proto...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Chaturvedi, Shruti, Dhaliwal, Noor, Hussain, Sarah, Dane, Kathryn, Upreti, Harshvardhan, Braunstein, Evan M., Yuan, Xuan, Sperati, C. John, Moliterno, Alison R., Brodsky, Robert A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Thrombosis and Hemostasis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948299/
https://ncbi.nlm.nih.gov/pubmed/33683339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003175
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados